Skip to main content
SpringerLink
Log in

Effects of Blockade of Cholinesterase on Negative Disorders in Schizophrenia

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objective. To assess the possible influence of blockade of cholinesterase on negative disorders in schizophrenia patients. Materials and methods. The study included 26 patients (including 13 women) with paranoid schizophrenia, episodic-progressive form (ICD-10), in remission and receiving stable antipsychotic therapy. Mean age was 40.4 (SD 11.7) years. The following psychometric scales were used: the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning Scale (GAF), a neurocognitive method (the Brief Assessment of Cognition in Schizophrenia, BACS), and projective psychological methods (Rorschach test). Results and conclusions. These studies showed that augmentation of maintenance antipsychotic therapy with a cholinesterase blocker was found to be an effective means of influencing negative disorders, particularly decreasing the extent of symptoms of emotional deficit. Improvements in cognitive functioning on the BACS occurred independently of changes in the severity of negative disorders on the PANSS. The Rorschach test demonstrated improvements in conventional orientation of thinking in the patients. There were no cases with exacerbation of psychotic symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. J. Rabinowitz, S. Z. Levine, G. Garibaldi, et al., “Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data,” Schizophr. Res., 137, No. 1–3, 147–150 (2012), https://doi.org/10.1016/j.schres.2012.01.015.

    Article  PubMed  Google Scholar 

  2. S. E. Hyman and W. S. Fenton, “Medicine. What are the right targets for psychopharmacology?” Science, 299, No. 5605, 350–351 (2003), https://doi.org/10.1126/science.1077141.

    Article  CAS  PubMed  Google Scholar 

  3. C. Arango, R. W. Buchanan, B. Kirkpatrick, and W. T. Carpenter, “The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms,” Eur. Psychiatry, 19, No. 1, 21–26 (2004), https://doi.org/10.1016/j.eurpsy.2003.10.004.

    Article  PubMed  Google Scholar 

  4. W. T. Carpenter and J. M. Davis, “Another view of the history of antipsychotic drug discovery and development,” Mol. Psychiatry, 17, No. 12, 1168–1173 (2012), https://doi.org/10.1038/mp.2012.121.

    Article  CAS  PubMed  Google Scholar 

  5. S. P. Singh, V. Singh, N. Kar, and K. Chan, “Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta- analysis,” Br. J. Psychiatry, 197, No. 3, 174–179 (2010), https://doi.org/10.1192/bjp.bp.109.067710.

    Article  PubMed  Google Scholar 

  6. Y. Levkovitz, S. Mendlovich, S. Riwkes, et al., “A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia,” J. Clin. Psychiatry, 71, No. 2, 138–149 (2010), https://doi.org/10.4088/JCP.08m04666yel.

    Article  CAS  PubMed  Google Scholar 

  7. I. B. Chaudhry, J. Hallak, N. Husain, et al., “Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment,” J. Psychopharmacol., 26, No. 9, 1185–1193 (2012), https://doi.org/10.1177/0269881112444941.

    Article  CAS  PubMed  Google Scholar 

  8. J. A. Bodkin, B. M. Cohen, M. S. Salomon, et al., “Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine,” J. Nerv. Ment. Dis., 184, No. 5, 295–301 (1996), https://doi.org/10.1097/00005053-199605000-00005.

    Article  CAS  PubMed  Google Scholar 

  9. A. Amiri, A.-A. Noorbala, A.-A. Nejatisafa, et al., “Efficacy of selegiline add-on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study,” Hum. Psychopharmacol., 23, No. 2, 79–86 (2008), https://doi.org/10.1002/hup.902.

    Article  CAS  PubMed  Google Scholar 

  10. T. Jungerman, D. Rabinowitz, and E. Klein, “Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study,” J. Clin. Psychopharmacol., 19, No. 6, 522–525 (1999), https://doi.org/10.1097/00004714-199912000-00006.

    Article  CAS  PubMed  Google Scholar 

  11. U. Heresco-Levy, M. Ermilov, P. Lichtenberg, et al., “High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia,” Biol. Psychiatry, 55, No. 2, 165–171 (2004), https://doi.org/10.1016/s0006-3223(03)00707-8.

    Article  CAS  PubMed  Google Scholar 

  12. A. E. Evins, S. M. Fitzgerald, L. Wine, et al., “Placebo-controlled trial of glycine added to clozapine in schizophrenia,” Am. J. Psychiatry, 157, No. 5, 826–828 (2000), https://doi.org/10.1176/appi.ajp.157.5.826.

    Article  CAS  PubMed  Google Scholar 

  13. D. C. Goff, C. Cather, J. D. Gottlieb, et al., “Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study,” Schizophr. Res., 106, No. 2–3, 320–327 (2008), https://doi.org/10.1016/j.schres.2008.08.012.

    Article  PubMed  PubMed Central  Google Scholar 

  14. D. C. Goff, G. Tsai, J. Levitt, et al., “A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia,” Arch. Gen. Psychiatry, 56, No. 1, 21–27 (1999), https://doi.org/10.1001/archpsyc.56.1.21.

    Article  CAS  PubMed  Google Scholar 

  15. E. J. Duncan, S. Szilagyi, M. P. Schwartz, et al., “Effects of D-cycloserine on negative symptoms in schizophrenia,” Schizophr. Res., 71, No. 2–3, 239–248 (2004), https://doi.org/10.1016/j.schres.2004.03.013.

    Article  PubMed  Google Scholar 

  16. G. E. Tsai, P. Yang, Y.-C. Chang, and M.-Y. Chong, “D-Alanine added to antipsychotics for the treatment of schizophrenia,” Biol. Psychiatry, 59, No. 3, 230–234 (2006), https://doi.org/10.1016/j.biopsych.2005.06.032.

    Article  CAS  PubMed  Google Scholar 

  17. R. W. Buchanan, D. C. Javitt, S. R. Marder, et al., “The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments,” Am. J. Psychiatry, 164, No. 10, 1593–1602 (2007), https://doi.org/10.1176/appi.ajp.2007.06081358.

    Article  PubMed  Google Scholar 

  18. S. M. Stahl, A. Malla, J. W. Newcomer, et al., “A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial,” J. Clin. Psychopharmacol., 30, No. 4, 425–430 (2010), https://doi.org/10.1097/JCP.0b013e3181e69042.

    Article  CAS  PubMed  Google Scholar 

  19. V. L. Stauffer, B. A. Millen, S. Andersen, et al., “Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo,” Schizophr. Res., 150, No. 2–3, 434–441 (2013), https://doi.org/10.1016/j.schres.2013.08.020.

    Article  PubMed  Google Scholar 

  20. C. E. Marx, R. S. E. Keefe, R. W. Buchanan, et al., “Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia,” Neuropsychopharmacology, 34, No. 8, 1885–1903 (2009), https://doi.org/10.1038/npp.2009.26.

    Article  CAS  PubMed  Google Scholar 

  21. M. S. Ritsner, A. Gibel, T. Shleifer, et al., “Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial,” J. Clin. Psychiatry, 71, No. 10, 1351–1362 (2010), https://doi.org/10.4088/JCP.09m05031yel.

    Article  CAS  PubMed  Google Scholar 

  22. J. Singh, K. Kour, and M. B. Jayaram, “Acetylcholinesterase inhibitors for schizophrenia,” Cochrane Database Syst. Rev., 1, CD007967 (2012), https://doi.org/10.1002/14651858.CD007967.pub2.

    Article  PubMed  Google Scholar 

  23. R. R. Conley, D. L. Boggs, D. L. Kelly, et al., “The effects of galantamine on psychopathology in chronic stable schizophrenia,” Clin. Neuropharmacol., 32, No. 2, 69–74 (2009), https://doi.org/10.1097/WNF.0B013E31816F2795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. S. Akhondzadeh, M. Gerami, M. Noroozian, et al., “A 12-week, double- blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, No. 8, 1810–1815 (2008), https://doi.org/10.1016/j.pnpbp.2008.08.001.

    Article  CAS  PubMed  Google Scholar 

  25. R. Freedman, A. Olincy, R. W. Buchanan, et al., “Initial phase 2 trial of a nicotinic agonist in schizophrenia,” Am. J. Psychiatry, 165, No. 8, 1040–1047 (2008), https://doi.org/10.1176/appi.ajp.2008.07071135.

    Article  PubMed  PubMed Central  Google Scholar 

  26. J. A. Lieberman, G. Dunbar, A. C. Segreti, et al., “A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia,” Neuropsychopharmacology, 38, No. 6, 968–975 (2013), https://doi.org/10.1038/npp.2012.259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. I. V. Damulin, S. A. Zhivolupov, O. S. Zaitsev, et al., Neiromidin in Clinical Practice, Medical Information Agency, Moscow (2016), 2nd ed.

    Google Scholar 

  28. P. R. Kamchatnov, F. K. Dzugaeva, A. V. Chugunov, and A. Yu. Kazakov, “Use of ipidacrine in patients with peripheral nervous system diseases,” Ross. Med. Zh., 12, No. 1, 44–48 (2018).

    Google Scholar 

  29. M. V. Chelyapina, E. V. Sharova, and O. S. Zaitsev, “Effects of ipidacrine (Neiromidin) on EEG parameters in severe brain trauma,” Usp. Sovr. Estestvozn., 1, 38–40 (2008).

    Google Scholar 

  30. A. I. Fedin and E. Yu. Solov’eva, “Effects of Ipigrix on motor, sensory, and cognitive functions in patients with peripheral and central nervous system diseases in conditions of real clinical practice. Results from a multicenter observational study,” Meditsinsk. Alfavit., 2, No. 17, 9–12 (2018).

    Google Scholar 

  31. I. V. Damulin, D. A. Stepkina, and A. B. Lokshina, “Use of Neiromidin in mixed (vascular and Alzheimer’s) dementia,” Zh. Nevrol. Psikhiatr., 111, No. 2, 40–43 (2011).

    CAS  Google Scholar 

  32. M. A. Morozova, A. G. Beniashvili, T. E. Rupchev, et al., “Effects of the anticholinesterase drug Neiromidin in patients with schizophrenia with severe schizophrenic defi cits,” Zh. Nevrol. Psikhiatr., 108, No. 11, 28–35 (2008).

    CAS  Google Scholar 

  33. M. D. Mashkovskii, Medicines. Textbook for Doctors. A Handbook, Meditsina, Moscow (1993).

    Google Scholar 

  34. I. V. Burov, T. N. Robakidze, L. V. Kadysheva, et al., “Study of anti- amnesic activity of amiridin in a model of amnesic syndrome,” Byull. Eksperim. Biol. Med., 111, No. 6, 614–617 (1991).

    CAS  Google Scholar 

  35. I. V. Burov, T. D. Baimanov, L. V. Tat’ianenko, et al., “Effects of amiridin and tacrine, drugs effective in Alzheimer’s disease, on the activity of monoamine oxidase A and B,” Byull. Eksperim. Biol. Med., 113, No. 2, 149–150 (1992).

    CAS  Google Scholar 

  36. J. Kojima and K. Onodera, “Effects of NIK-247 and tacrine on muscarinic receptor subtypes in rats,” Gen. Pharmacol., 30, No. 4, 537– 541 (1998), https://doi.org/10.1016/s0306-3623(97)00303-0.

    Article  CAS  PubMed  Google Scholar 

  37. S. Yoshida and N. Suzuki, “Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats,” Eur. J. Pharmacol., 250, No. 1, 117–124 (1993), https://doi.org/10.1016/0014-2999(93)90628-u.

    Article  CAS  PubMed  Google Scholar 

  38. K. Onodera, J. Kojima, and M. Wachi, “Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water, Nihon Shinkei Seishin Yakurigaku Zasshi, 18, No. 2, 33–37 (1998).

    CAS  PubMed  Google Scholar 

  39. H. Ogura, T. Kosasa, Y. Kuriya, and Y. Yamanishi, “Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro,” Methods Find. Exp. Clin. Pharmacol., 22, No. 8, 609–613 (2000), https://doi.org/10.1358/mf.2000.22.8.701373.

    Article  CAS  PubMed  Google Scholar 

  40. S. I. Gavrilova, V. A. Kontsevoi, and N. M. Mikhailova, “Comparative efficacy of amiridin treatment for Alzheimer’s type dementia and vascular dementia,” Vopr. Gerontopsikhiatrii, 5, 132–151 (1991).

    Google Scholar 

  41. E. Ivanova, A. Khan, L. Liharska, et al., “Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data,” Innov. Clin. Neurosci., 15, No. 9–10, 32–48 (2018).

    PubMed  PubMed Central  Google Scholar 

  42. R. S. E. Keefe, P. D. Harvey, T. E. Goldberg, et al., “Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS),” Schizophr. Res., 102, No. 1–3, 108–115 (2008), https://doi.org/10.1016/j.schres.2008.03.024.

    Article  PubMed  Google Scholar 

  43. G. R. Sarkisyan, I. Ya. Gurovich, and R. S. Keefe, “Normative data for the Russian population and standardization of the ‘Brief Assessment of Cognition in Schizophrenia’ (BACS),” Sots. Klin. Psikhiatr., 3, 13–20 (In Russ.) (2010).

  44. R. C. Hall, “Global assessment of functioning. A modified scale,” Psychosomatics, 36, No. 3, 267–275 (1995), https://doi.org/10.1016/S0033-3182(95)71666-8.

    Article  CAS  PubMed  Google Scholar 

  45. J. E. Exner, Jr., The Rorschach: A Comprehensive System: Interpretation, John Wiley & Sons, New York (1991), Vol. 2, 2nd ed.

    Google Scholar 

  46. M. A. Assanovich, An Integrated Rorschach Psychodiagnostic System, Kogito-Tsentr, Moscow (2011).

    Google Scholar 

  47. B. R. Rund, “A review of longitudinal studies of cognitive functions in schizophrenia patients,” Schizophr. Bull., 24, No. 3, 425–435 (1998), https://doi.org/10.1093/oxfordjournals.schbul.a033337.

    Article  CAS  PubMed  Google Scholar 

  48. G. Heydebrand, M. Weiser, J. Rabinowitz, et al., “Correlates of cognitive deficits in first episode schizophrenia,” Schizophr. Res., 68, No. 1, 1–9 (2004), https://doi.org/10.1016/S0920-9964(03)00097-5.

    Article  PubMed  Google Scholar 

  49. G. P. Strauss and J. M. Gold, “A new perspective on anhedonia in schizophrenia,” Am. J. Psychiatry, 169, No. 4, 364–373 (2012), https://doi.org/10.1176/appi.ajp.2011.11030447.

    Article  PubMed  PubMed Central  Google Scholar 

  50. J. M. Gold, J. A. Waltz, K. J. Prentice, et al., “Reward processing in schizophrenia: a deficit in the representation of value,” Schizophr. Bull., 34, No. 5, 835–847 (2008), https://doi.org/10.1093/schbul/sbn068.

    Article  PubMed  PubMed Central  Google Scholar 

  51. T. Wykes, V. Huddy, C. Cellard, et al., “A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes,” Am. J. Psychiatry, 168, No. 5, 472–485 (2011), https://doi.org/10.1176/appi.ajp.2010.10060855.

    Article  PubMed  Google Scholar 

  52. A. Farreny, J. Aguado, S. Ochoa, et al., “The role of negative symptoms in the context of cognitive remediation for schizophrenia,” Schizophr. Res., 150, No. 1, 58–63 (2013), https://doi.org/10.1016/j.schres.2013.08.008.

    Article  PubMed  Google Scholar 

  53. M. Cella, S. Swan, E. Medin, et al., “Metacognitive awareness of cognitive problems in schizophrenia: exploring the role of symptoms and self-esteem,” Psychol. Med., 44, No. 3, 469–476 (2014), https://doi.org/10.1017/S0033291713001189.

    Article  CAS  PubMed  Google Scholar 

  54. M. Cella, C. Reeder, and T. Wykes, “It is all in the factors: effects of cognitive remediation on symptom dimensions,” Schizophr. Res., 156, No. 1, 60–62 (2014), https://doi.org/10.1016/j.schres.2014.03.032.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mental Health Research Center, Moscow, Russia

    M. A. Morozova, S. S. Potanin, G. E. Rupchev, D. S. Burminskiy, T. A. Lepilkina & A. G. Beniashvili

  2. Lomonosov Moscow State University, Moscow, Russia

    G. E. Rupchev

Authors
  1. M. A. Morozova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. S. Potanin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. E. Rupchev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. S. Burminskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. A. Lepilkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. G. Beniashvili
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. E. Rupchev.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 8, Iss. 1, pp. 37–44, August, 2021.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morozova, M.A., Potanin, S.S., Rupchev, G.E. et al. Effects of Blockade of Cholinesterase on Negative Disorders in Schizophrenia. Neurosci Behav Physi 52, 607–613 (2022). https://doi.org/10.1007/s11055-022-01284-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-022-01284-6

Keywords

Search

Navigation